Trials / Withdrawn
WithdrawnNCT01912040
Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use
A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Nova Scotia Health Authority · Academic / Other
- Sex
- All
- Age
- 1 Month
- Healthy volunteers
- Not accepted
Summary
Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.
Detailed description
We will be assessing for adverse reactions of patients injected with locally manufactured 123 Iodine MIBG. With monitoring of blood pressure and heart rate following injection and any potential immediate side effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Administration of 123Iodine MIBG | Patients will be administered the locally produced 123 Iodine MIBG |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2013-07-30
- Last updated
- 2022-11-14
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01912040. Inclusion in this directory is not an endorsement.